Tarsus Pharmaceuticals (TARS) Free Cash Flow Growth (1y) (2020 - 2026)
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Free Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 38.94% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 96.00% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 152.82% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 31.57% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 58.53% |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn | 288.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 288.08% |
| Mar 31, 2026 | -43.45% |
| Dec 31, 2025 | 158.29% |
| Sep 30, 2025 | 282.98% |
| Jun 30, 2025 | -96.78% |
| Mar 31, 2025 | 44.05% |
| Dec 31, 2024 | 43.42% |
| Sep 30, 2024 | 72.71% |
| Jun 30, 2024 | 37.26% |
| Mar 31, 2024 | -70.16% |
| Dec 31, 2023 | -257.56% |
| Sep 30, 2023 | -75.00% |
| Jun 30, 2023 | -461.81% |
| Mar 31, 2023 | -44.43% |
| Dec 31, 2022 | 5.36% |
| Sep 30, 2022 | -380.21% |
| Jun 30, 2022 | -122.49% |
| Mar 31, 2022 | -18.38% |
| Dec 31, 2021 | -16.67% |
| Sep 30, 2021 | 199.54% |